Protagenic Therapeutics Overview

  • Year Founded
  • 1994

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • PTIX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.42
  • (As of Wednesday Closing)

Protagenic Therapeutics General Information

Description

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Contact Information

Formerly Known As
Atrinsic
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 149 Fifth Avenue
  • Suite 500
  • New York, NY 10010
  • United States
+1 (929)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OTCM
Corporate Office
  • 149 Fifth Avenue
  • Suite 500
  • New York, NY 10010
  • United States
+1 (929)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Protagenic Therapeutics Stock Performance

As of 18-Nov-2026, Protagenic Therapeutics’s stock price is $0.42. Its current market cap is $760K with 1.81M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.42 $0.46 $0.13 - $2.38 $760K 1.81M 12.6K $2.33

Protagenic Therapeutics Financials Summary

As of 30-Sep-2026, Protagenic Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Dec-2024
EV 900 3,010 (370) 2,444
Revenue 0 0 0 0
EBITDA 6,976 2,912 (2,553) (5,519)
Net Income 5,664 1,368 (3,592) (5,525)
Total Assets 2,272 3,650 1,956
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Protagenic Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Protagenic Therapeutics‘s full profile, request access.

Request a free trial

Protagenic Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to t
Drug Discovery
New York, NY
3 As of 2026

San Diego, CA
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Protagenic Therapeutics Competitors (17)

One of Protagenic Therapeutics’s 17 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
Lamassu Venture Capital-Backed Durham, NC
Calliditas Therapeutics France Corporate Backed or Acquired Saint-Julien- en-Genevois, France
Hansa Biopharma Corporation Lund, Sweden
Omeros Formerly VC-backed Seattle, WA
You’re viewing 5 of 17 competitors. Get the full list »

Protagenic Therapeutics Patents

Protagenic Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2960804-T3 Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for the treatment of opioid addiction Active 13-Mar-2018
CA-3093841-A1 Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction Pending 13-Mar-2018
EP-3765056-A1 Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction Active 13-Mar-2018
EP-3765056-B1 Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction Active 13-Mar-2018
EP-3765056-C0 Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction Active 13-Mar-2018 A61K38/17
To view Protagenic Therapeutics’s complete patent history, request access »

Protagenic Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Protagenic Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Protagenic Therapeutics‘s full profile, request access.

Request a free trial

Protagenic Therapeutics Acquisitions (1)

Protagenic Therapeutics’s most recent deal was a Merger/Acquisition with Atrinsic. The deal was made on 12-Feb-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Atrinsic 12-Feb-2016 Merger/Acquisition Media and Information Services (B2B)
To view Protagenic Therapeutics’s complete acquisitions history, request access »

Protagenic Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Protagenic Therapeutics’s complete esg history, request access »

Protagenic Therapeutics FAQs

  • When was Protagenic Therapeutics founded?

    Protagenic Therapeutics was founded in 1994.

  • Where is Protagenic Therapeutics headquartered?

    Protagenic Therapeutics is headquartered in New York, NY.

  • What is the size of Protagenic Therapeutics?

    Protagenic Therapeutics has 3 total employees.

  • What industry is Protagenic Therapeutics in?

    Protagenic Therapeutics’s primary industry is Drug Discovery.

  • Is Protagenic Therapeutics a private or public company?

    Protagenic Therapeutics is a Public company.

  • What is Protagenic Therapeutics’s stock symbol?

    The ticker symbol for Protagenic Therapeutics is PTIX.

  • What is the current stock price of Protagenic Therapeutics?

    As of 18-Nov-2026 the stock price of Protagenic Therapeutics is $0.42.

  • What is the current market cap of Protagenic Therapeutics?

    The current market capitalization of Protagenic Therapeutics is $760K.

  • Who are Protagenic Therapeutics’s competitors?

    ACADIA Pharmaceuticals, Lamassu, Calliditas Therapeutics France, Hansa Biopharma, and Omeros are some of the 17 competitors of Protagenic Therapeutics.

  • What is Protagenic Therapeutics’s annual earnings per share (EPS)?

    Protagenic Therapeutics’s EPS for 12 months was $2.33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process